Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris

Biochemical and Biophysical Research Communications

Volumn 447, Issue 2, 2014, Pages 341-345

  Ueda, Youki ^a   Mori, Kyoko ^a   Satoh, Shinya ^a   Dansako, Hiromichi ^a   Ikeda, Masanori ^a   Kato, Nobuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Assay systems for anti HCV activity; Cordycepin; Cordyceps militaris; HCV RNA replication system; Hepatitis C virus

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CORDYCEPIN; ERGOSTEROL; FUNGAL EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIBAVIRIN; TEPRENONE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CHINESE MEDICINE; CORDYCEPS; DRUG CAPSULE; DRUG DETERMINATION; DRUG EFFECT; FUNGAL STRAIN; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CORDYCEPS MILITARIS; FUNGI; HEPATITIS C VIRUS; RENILLA LUCIFERASE;

ASSAY SYSTEMS FOR ANTI-HCV ACTIVITY; CORDYCEPIN; CORDYCEPS MILITARIS; HCV RNA-REPLICATION SYSTEM; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; CORDYCEPS; DEOXYADENOSINES; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; ERGOSTEROL; FUNGAL CAPSULES; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; ORAL HEALTH; RIBAVIRIN; RNA, VIRAL; VIRUS REPLICATION;

EID: 84899909666     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.150     Document Type: Article

References (22)

1. D.L. Thomas Hepatitis C epidemiology Curr. Top. Microbiol. Immunol. 242 2000 25 41
2. N. Kato, M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis Proc. Natl. Acad. Sci. USA 87 1990 9524 9528
3. N. Kato Molecular virology of hepatitis C virus Acta Med. Okayama 55 2001 133 159
4. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection, Practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
5. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N. Engl. J. Med. 368 2013 1907 1917
6. K. Chayama, C.N. Hayes, W. Ohishi, and Y. Kawakami Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines J. Gastroenterol. 48 2013 1 12
7. T.K. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat. Med. 19 2013 837 849
8. N. Kato, K. Mori, K. Abe, H. Dansako, M. Kuroki, Y. Ariumi, T. Wakita, and M. Ikeda Efficient replication systems for hepatitis C virus using a new human hepatoma cell line Virus Res. 146 2009 41 50
9. M. Ikeda, K. Abe, H. Dansako, T. Nakamura, K. Naka, and N. Kato Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system Biochem. Biophys. Res. Commun. 329 2005 1350 1359
10. K. Mori, M. Ikeda, Y. Ariumi, and N. Kato Gene expression profile of Li23, a new human hepatoma cell line that enables robust hepatitis C virus replication: comparison with HuH-7 and other hepatic cell lines Hepatol. Res. 40 2010 1248 1253
11. K. Mori, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, and N. Kato Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system Virus Res. 157 2011 61 70
12. K. Mori, Y. Ueda, Y. Ariumi, H. Dansako, M. Ikeda, and N. Kato Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C Virus Genes 44 2012 374 381
13. K. Mori, O. Hiraoka, M. Ikeda, Y. Ariumi, A. Hiramoto, Y. Wataya, and N. Kato Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin Hepatology 58 2013 1236 1244
14. Y. Ueda, K. Mori, Y. Ariumi, M. Ikeda, and N. Kato Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents Biochem. Biophys. Res. Commun. 409 2011 663 668
15. H.S. Kim, Y. Nagai, K. Ono, K. Begum, Y. Wataya, Y. Hamada, K. Tsuchiya, A. Masuyama, M. Nojima, and K.J. McCullough Synthesis and antimalarial activity of novel medium-sized 1,2,4,5-tetraoxacycloalkanes J. Med. Chem. 44 2001 2357 2361
16. H.S. Kim, K. Begum, N. Ogura, Y. Wataya, Y. Nonami, T. Ito, A. Masuyama, M. Nojima, and K.J. McCullough Antimalarial activity of novel 1,2,5,6-tetraoxacycloalkanes and 1,2,5-trioxacycloalkanes J. Med. Chem. 46 2003 1957 1961
17. Y. Ueda, M. Takeda, K. Mori, H. Dansako, T. Wakita, H.S. Kim, A. Sato, Y. Wataya, M. Ikeda, and N. Kato New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication PLoS One 8 2013 e72519
18. G. Nishimura, M. Ikeda, K. Mori, T. Nakazawa, Y. Ariumi, H. Dansako, and N. Kato Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents Antivir. Res. 82 2009 42 50
19. N. Kato, K. Sugiyama, K. Namba, H. Dansako, T. Nakamura, M. Takami, K. Naka, A. Nozaki, and K. Shimotohno Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro Biochem. Biophys. Res. Commun. 306 2003 756 766
20. M. Yano, M. Ikeda, K. Abe, H. Dansako, S. Ohkoshi, Y. Aoyagi, and N. Kato Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture Antimicrob. Agents Chemother. 51 2007 2016 2027
21. M. Yano, M. Ikeda, K. Abe, Y. Kawai, M. Kuroki, K. Mori, H. Dansako, Y. Ariumi, S. Ohkoshi, Y. Aoyagi, and N. Kato Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase Hepatology 50 2009 678 688
22. H.S. Tuli, A.K. Sharma, S.S. Sandhu, and D. Kashyap Cordycepin: a bioactive metabolite with therapeutic potential Life Sci. 93 2013 863 869